ArticlePloS one2018
Whole blood transcriptional profiles as a prognostic tool in complete and incomplete Kawasaki Disease.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A consensus immune dysregulation framework for sepsis and critical illnesses.Nature medicine · 2025Guideline
- Monocyte Single-Cell-Type Gene Expression Analysis Differentiates Kawasaki Disease From Viral Infection With High Specificity.Journal of cellular and molecular medicine · 2026Article
- Protective role of complement signaling in Kawasaki disease vasculitis.JCI insight · 2026Article
- Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Mitophagy.Circulation research · 2026Article
- Oxidative stress-related genes in Kawasaki disease: a multi-omics Mendelian randomization study.Italian journal of pediatrics · 2026Article
- The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease.Frontiers in immunology · 2026Article
- A lipid-related transcriptomic signature for distinguishing Kawasaki disease from febrile infections: a Mendelian randomization and machine-learning study.Frontiers in immunology · 2026Article
- Bioinformatics analysis of immune-related differentially expressed genes in Kawasaki disease.Scientific reports · 2025Article
- Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Autophagy and Mitophagy.bioRxiv : the preprint server for biology · 2025Article
- Article
- Identification of key ferroptosis‑related biomarkers in Kawasaki disease by clinical and experimental validation.Biomedical reports · 2025Article
- Flavonoid compound fromFrontiers in cellular and infection microbiology · 2025Article
- Identification of novel metabolism-related biomarkers of Kawasaki disease by integrating single-cell RNA sequencing analysis and machine learning algorithms.Frontiers in immunology · 2025Article
- Platelets in Kawasaki disease: mediators of vascular inflammation.Nature reviews. Rheumatology · 2024Review
- Inhibition of IL-1 Ameliorates Cardiac Dysfunction and Arrhythmias in a Murine Model of Kawasaki Disease.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- Human Umbilical Cord Mesenchymal Stem Cells Repair Endothelial Injury and Dysfunction by Regulating NLRP3 to Inhibit Endothelial Cell Pyroptosis in Kawasaki Disease.Inflammation · 2024Article
- Susceptibility ofHeliyon · 2024Article
- Systems immunology of transcriptional responses to viral infection identifies conserved antiviral pathways across macaques and humans.Cell reports · 2024Article
- Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis.JCI insight · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundEarly identification of children with Kawasaki Disease (KD) is key for timely initiation of intravenous immunoglobulin (IVIG) therapy. However, the diagnosis of the disease remains challenging, especially in children with an incomplete presentation (inKD). Moreover, we currently lack objective tools for identification of non-response (NR) to IVIG.
methodsChildren with KD were enrolled and samples obtained before IVIG treatment and sequentially at 24 h and 4-6 weeks post-IVIG in a subset of patients. We also enrolled children with other febrile illnesses [adenovirus (AdV); group A streptococcus (GAS)] and healthy controls (HC) for comparative analyses. Blood transcriptional profiles were analyzed to define: a) the cKD and inKD biosignature, b) compare the KD signature with other febrile illnesses and, c) identify biomarkers predictive of clinical outcomes.
resultsWe identified a cKD biosignature (n = 39; HC, n = 16) that was validated in two additional cohorts of children with cKD (n = 37; HC, n = 20) and inKD (n = 13; HC, n = 8) and was characterized by overexpression of inflammation, platelets, apoptosis and neutrophil genes, and underexpression of T and NK cell genes. Classifier genes discriminated KD from adenovirus with higher sensitivity and specificity (92% and 100%, respectively) than for GAS (75% and 87%, respectively). We identified a genomic score (MDTH) that was higher at baseline in IVIG-NR [median 12,290 vs. 5,572 in responders, p = 0.009] and independently predicted IVIG-NR.
conclusionA reproducible biosignature from KD patients was identified, and was similar in children with cKD and inKD. A genomic score allowed early identification of children at higher risk for non-response to IVIG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.